Exablate for LIFU Neuromodulation in Patients With Opioid Use Disorder (OUD)

NACompletedINTERVENTIONAL
Enrollment

5

Participants

Timeline

Start Date

September 19, 2023

Primary Completion Date

July 8, 2024

Study Completion Date

April 25, 2025

Conditions
Opioid Use Disorder
Interventions
DEVICE

Exablate Model 4000 Type 2.0/2.1

There are two treatment stages. In both stages, the subject will receive both the sham and active ExAblate treatment, and be evaluated for 90 days post-treatment for adverse events. During Stage 1 the subject will receive the moderate intensity Exablate LIFU procedure. During Stage2, the subject will receive the enhanced intensity ExAblate LIFU procedure. The subjects are blinded as to the order of the sham vs active treatment.

Trial Locations (1)

26506

West Virginia University: Rockefeller Neuroscience Institute, Morgantown

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

National Institute on Drug Abuse (NIDA)

NIH

collaborator

InSightec

INDUSTRY

lead

West Virginia University

OTHER